WST logo

WEST PHARMACEUTICAL SERVICES

WSTNYSE
πŸ† #417 by market capEarnings Oct 29US Equity
$403.90β–² $5.77 (+1.45%)
Market closed Β· at close
πŸ””
Track WST
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.4%
7dβ–² 2.5%
14dβ–² 5.4%
30dβ–² 7.2%
ytdβ–² 46.8%
1yβ–² 41.7%
🏦Market Cap
$28.42B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
6.3%
Slowing
πŸ“ŠGross Margin
36.8%
Healthy
πŸ’΅FCF Margin
13.1%
Healthy
βš–οΈP/S Ratio
8.5x
Elevated
Otter Score
68
Fair

Trading Snapshot

Day Range
$397.47 – $404.76
52-Week Range
$223.83 – $404.85
Volume (shares)
67,088
Avg Volume (shares)
β€”
Shares Outstanding
70.4M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$3.07B
Last Q Revenue
$872M
P/E Ratio
51.3
P/S Ratio
8.5x
EPS (TTM)
$7.98
Dividend Yield
0.22%
Dilution (1yr)
βˆ’1.4%
WST logo

WEST PHARMACEUTICAL SERVICES

WST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3.1Bβ–² +6.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
35.9%β–² +3.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$617Mβ–² +3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$469Mβ–² +69.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
72.7Mβ–Ό βˆ’1.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$470Mβ–² +$288M YoY
StockOtter Β· stockotter.space

About WEST PHARMACEUTICAL SERVICES

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
22 analysts
Strong Buy7
Buy14
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.